Anamorelin vs MK-677: Comparing Oral Ghrelin-Receptor Agonists in Research
Anamorelin's Phase III ROMANA trials and MK-677's case-report data offer different evidence bases for ghrelin research; compare mechanisms and FDA status.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Anamorelin and MK-677 (ibutamoren) are both orally bioavailable ghrelin-receptor agonists studied in research settings, but they diverge sharply in target population, evidence stage, and regulatory trajectory — a distinction researchers comparing the two ghrelin-mimetic secretagogues need up front.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Anamorelin is a selective ghrelin receptor (GHS-R1a) agonist developed specifically for cancer-associated cachexia and evaluated in Phase III trials (the ROMANA program), while MK-677 is a broader-spectrum, non-selective ghrelin mimetic studied across growth-hormone deficiency, sarcopenia, and body-composition research without reaching a comparable regulatory endpoint.
TL;DR:
- Both compounds activate the ghrelin receptor (GHS-R1a) to stimulate growth hormone and appetite-related signaling, but through different selectivity profiles.
- Anamorelin has completed Phase III oncology trials (ROMANA 1/2/3) with lean-body-mass and appetite endpoints; MK-677 research is largely Phase I/II and observational.
- Anamorelin's evidence base centers on cancer-cachexia populations; MK-677's spans GH-deficiency, aging, and case-report-level body composition data.
- Neither compound currently holds FDA approval in the United States, though their regulatory histories differ substantially.
- MK-677 case data show measurable hepatic and lipid biomarker shifts alongside body-composition changes, an important safety signal for research design.
Anamorelin: Mechanism and Evidence Base
Anamorelin is a selective ghrelin receptor (GHS-R1a) agonist investigated as a therapeutic candidate for cancer-related anorexia-cachexia syndrome. Preclinical and clinical research indicates it binds hypothalamic GHS-R1a receptors, mimicking endogenous ghrelin signaling to activate orexigenic (appetite-promoting) neuropeptide Y and agouti-related peptide pathways. A second, distinct arm of its proposed mechanism involves suppression of pro-inflammatory cytokines, including IL-6 and TNF-α, which are implicated in the protein catabolism that drives cachexia. Full compound data, including chemistry and citation history, is available on the Anamorelin library profile.
The compound's primary evidence base is the ROMANA trial program (ROMANA 1, ROMANA 2, ROMANA 3), Phase III studies in patients with non-small cell lung cancer and cachexia, published in The Lancet Oncology (Temel et al., 2016; PMID 41950300 in this citation set references a 2026 umbrella review of pharmacological cachexia treatments, PROSPERO registration CRD420251131074, that re-analyzes this and related trial data). Across the program, anamorelin produced statistically significant increases in lean body mass and total body weight relative to placebo. Handgrip strength, a secondary functional endpoint, did not reach significance in all cohorts — a frequently cited limitation when researchers compare appetite/mass endpoints against functional strength outcomes.
MK-677: Mechanism and Evidence Base
MK-677 (ibutamoren) is a growth hormone secretagogue that selectively activates the ghrelin receptor to stimulate pulsatile endogenous growth hormone and insulin-like growth factor-1 (IGF-1) secretion. Unlike anamorelin's oncology-cachexia focus, MK-677's published research spans a broader set of applications, including growth hormone deficiency models, sarcopenia, and — in more recent case-level literature — body composition research in combination with other investigational agents. The full chemistry and citation record is available on the MK-677 library profile.
A 2022 case report (PMID 36303408, published in a peer-reviewed endocrinology-adjacent format) documented a 25-year-old male's five-week co-administration of MK-677 with LGD-4033, a selective androgen receptor modulator. The case recorded pre- to on-cycle increases in total lean body mass (+3.1%), trunk lean mass (+6.6%), and total body mass (+6.0%), alongside a concurrent fat mass increase (+15.4%). The same case documented substantial hormonal and hepatic biomarker shifts: free testosterone declined 85.7%, total testosterone declined 62.3%, sex hormone-binding globulin decreased 79.6%, aspartate aminotransferase rose 95.8%, and alanine aminotransferase rose 205.0%. Post-cycle follow-up showed incomplete recovery of several markers, including persistently suppressed follicle-stimulating hormone. Because this is case-report-level evidence rather than a randomized controlled trial, researchers should treat the magnitude of these findings as illustrative rather than generalizable — a distinction relevant when comparing MK-677's evidence quality to anamorelin's Phase III program. For a closer look at MK-677 against a related ghrelin-receptor peptide, see the MK-677 vs Ipamorelin comparison.
Side-by-Side Comparison
| Attribute | Anamorelin | MK-677 (ibutamoren) |
|---|---|---|
| Receptor target | Ghrelin receptor (GHS-R1a), selective | Ghrelin receptor (GHS-R1a), non-peptide agonist |
| Route studied | Oral | Oral |
| Primary research population | Cancer-associated cachexia/anorexia | GH deficiency, sarcopenia, body composition |
| Most advanced evidence | Phase III (ROMANA 1/2/3) | Phase I/II trials plus case-report literature |
| Reported biomarker effects | Reduced IL-6, TNF-α; increased lean mass | Altered testosterone, SHBG, hepatic enzymes, lipids |
| US regulatory status | Not FDA-approved; Complete Response Letter history | Not FDA-approved; investigational research compound |
| WADA relevance | Ghrelin-receptor agonist class of research interest | Ghrelin-receptor agonist class of research interest |
Differential Research Applications
The two compounds tend to appear in different research contexts because their evidence bases answer different questions. Anamorelin's dataset is built around a single, well-defined clinical population — cancer patients with measurable cachexia — and researchers citing it are typically interested in appetite stimulation and lean-mass preservation in a catabolic disease state. MK-677's literature, by contrast, is more heterogeneous: growth hormone axis research, aging-related body composition studies, and more recently, case-level reports examining co-administration effects with other investigational compounds. Researchers designing comparative protocols often use the half-life comparison tool alongside the evidence explorer to cross-reference how far along each compound's evidence base has progressed before selecting a citation set. For a broader view of how ghrelin-receptor secretagogues compare against pulsatile GHRP-class peptides, the Ipamorelin vs Sermorelin comparison provides additional mechanistic context on the growth-hormone secretagogue category as a whole.
Regulatory and Compounding Status
Neither compound currently holds FDA approval for marketing in the United States. Anamorelin's Phase III program was submitted for FDA review, and public regulatory records indicate the agency issued a Complete Response Letter rather than an approval, despite the compound receiving marketing authorization for cancer cachexia in other jurisdictions. MK-677 has never advanced through an FDA New Drug Application to approval; it remains an investigational compound studied primarily in academic and industry-sponsored research settings, and it is not classified as a controlled substance in the same category as anabolic-androgenic steroids. Both compounds fall within the broader ghrelin-receptor-agonist class that regulatory bodies, including anti-doping authorities, monitor as a category of research interest. Researchers should consult current primary sources for jurisdiction-specific status rather than relying on secondary summaries, since compounding and research-chemical regulatory frameworks continue to evolve.
This shared regulatory ambiguity is one reason the two compounds are frequently discussed together despite their different clinical histories: both sit in a gray zone where a defined disease-population trial program (anamorelin's oncology cachexia work) and a broad research-chemical literature (MK-677's decades of GH-axis studies) have each failed, for different reasons, to translate into US marketing approval. Researchers tracking the ghrelin-receptor-agonist category as a whole — including how compounding pharmacies and research suppliers have responded to shifting 503A and 503B guidance — may find it useful to cross-reference this comparison against the site's broader coverage of FDA compounding policy for peptide-class research compounds, since enforcement posture toward ghrelin mimetics has generally tracked the same regulatory conversations affecting other growth-hormone secretagogues.
Cited Studies
- PMID 41950300 — "Pharmacological Treatments for Cancer-Related Anorexia-Cachexia Syndrome: An Umbrella Review of Systematic Reviews and Meta-Analyses" (2026). DOI: https://doi.org/10.1016/S1470-2045(16)00023-2
- PMID 36303408 — "LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report" (2022). DOI: https://doi.org/10.1210/jcem.83.2.4551
Frequently asked questions
Q: What is the main difference between anamorelin and MK-677?
A: Anamorelin is a selective ghrelin receptor agonist developed and studied specifically for cancer-associated cachexia through a completed Phase III trial program, while MK-677 is a broader-spectrum ghrelin mimetic studied across growth-hormone deficiency, aging, and body-composition research with a more heterogeneous, earlier-stage evidence base.
Q: Is anamorelin FDA approved?
A: Anamorelin has not received FDA approval for marketing in the United States. Public regulatory history indicates the agency issued a Complete Response Letter following its Phase III submission, even though the compound has secured approval in other jurisdictions for cancer-related cachexia.
Q: Does MK-677 increase growth hormone in research models?
A: Published research indicates MK-677 selectively activates the ghrelin receptor to stimulate pulsatile growth hormone and IGF-1 secretion. Case-level and trial data also report body composition changes, though these studies frequently document concurrent hormonal and hepatic biomarker shifts that warrant separate evaluation.
Q: What were the results of the ROMANA trials for anamorelin?
A: The ROMANA 1, 2, and 3 trials evaluated anamorelin in non-small cell lung cancer patients with cachexia and found statistically significant increases in lean body mass and total body weight compared with placebo. Handgrip strength, a secondary functional measure, did not reach statistical significance in all cohorts.
Q: Are anamorelin and MK-677 studied together in research protocols?
A: The compounds are not typically studied in combination in the published literature reviewed here. They are more often compared as alternative ghrelin-receptor research tools for different populations — anamorelin for cachexia-specific research and MK-677 for broader growth-hormone-axis and body-composition research.
See also:
- MK-677 vs Ipamorelin: Oral Ghrelin Mimetic vs Injectable GHRP — compares MK-677 against a peptide-class ghrelin receptor agonist with a different administration route.
- Anamorelin: Research Profile and WADA Status Update — a standalone profile covering anamorelin's regulatory and anti-doping classification in more depth.
- Ipamorelin vs Sermorelin: Growth Hormone Secretagogue Comparison — additional mechanistic context on the broader growth-hormone secretagogue research category.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.